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Novel 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives were synthesized and their potency in 
reducing the invasive behaviour of HT 1080 fibrosarcoma cells was evaluated. Structure—activity relationships 
were deduced from biological results and will be used in further design of new active compounds. In particular, 
the acetoxymethyl substituent found at the 6-position of previously described active compounds can be replaced 
by an acetamidomethyl substituent without loss of potency; while the presence of an aryl ester function at the 3-
position was preferred to a thioester or an amide function to induce marked biological activity. 
This work confirms the interest of aryl esters of 6-substituted coumarin-3-carboxylic acids as potential new anti-
cancer agents. 
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1. Introduction 
One of the most difficult problems arising during cancer therapy is the occurrence of cancer cell invasion 
responsible for the spread of tumour cells throughout the body. Such an event leading to metastases is an 
important cause of the bad prognosis of numerous cancers. Although anti-cancer chemotherapy mainly consists 
in the use of cytotoxic agents interfering with cell division, another research field has recently emerged with the 
design and identification of agents able to inhibit or limit the metastatic process. Indeed, many efforts are now 
focussed on the search of compounds interfering with the cancer cell invasion process and expressing anti-
angiogenic properties [1]. Examples of drugs, among which monoclonal antibodies and small molecules, are 
currently under clinical investigation and some of them have recently been approved for use in man in the 
treatment of several cancers associated or not with conventional chemotherapies or radiation therapies [2-9]. 
These drugs comprise vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) inhibitors 
(monoclonal antibodies) as well as VEGF and EGF receptor tyrosine kinase inhibitors (small-molecule 
inhibitors), but also matrix metalloproteinase (MMP), urokinase (uPA), cycloogygenase-2 (COX-2) or 
methionine aminopeptidase inhibitors [1]. 
We  recently  reported   that  two   synthetic   6-substituted coumarin-3-carboxylic     acid    derivatives,     3-
chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (1) and 3-bromophenyl 6-acetoxymethyl-
2-oxo-2H-1-benzopyran-3-carboxylate (2) (Fig. 1), expressed a marked potency in inhibiting cancer cell invasion 
in vitro and tumour growth in vivo [10]. Simple natural and synthetic coumarins such as esculetin (3), osthole (4) 
and the synthetic 6-nitro-substituted coumarin (5) (Fig. 1) are also known for a long time to exert anti-cancer 
properties, but, for most of them, by an unknown mechanism [11-14]. Recently reported coumarin derivatives 
such as G8935 (6) (Fig. 1), structurally related to 1 and 2 and identified as mitogen activated protein (MAP) 
kinase/extracellular signal-regulated kinase (ERK) kinase inhibitors (MEK1 inhibitors), raise the possibility that 
the coumarin-3-carboxylates 1 and 2 may exert their anti-cancer activity through inhibition of MEK1 [15]. 
Another recent work showed that coumarin-3-carboxamides (7, Fig. 1) tightly related to the chemical structure of 
1 and 2 selectively inhibited the tumour cells that have a high level of epidermal growth factor receptor (EGRF 
or erbB1) and erbB2 (HER2) receptor expression [16].  
Interestingly, the chemical structure of the active coumarins 1 and 2 may be compared to that of linomide 
(roquinimex) (8, Fig. 2), a quinolinone isostere of coumarins known to be an immunomodulator, but also 
expressing anti-angiogenic activity in vitro and in vivo [17-19]. Moreover, the preferred conformation adopted 
by linomide, as found in the crystal [20] (8'; Fig. 2), can be superimposed to the preferential conformation 
adopted, in the solid state and probably in solution, by aryl esters of coumarin-3-carboxylic acid derivatives (9'; 
Fig. 2) in accordance to recent published crystallographic and molecular modelling studies [21,22]. In contrast to 
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aryl esters of 6-substituted coumarin-3-carboxylic acids, the corresponding aryl amides 10 (Fig. 2) are not able to 
adopt such conformation because a strong intra-molecular hydrogen bound is established between the hydrogen 
atom of the exocyclic NH group and the lactonic carbonyl group [21]. 
Using coumarins 1 and 2 as lead compounds, the present work aimed at describing new examples of coumarin-3-
carboxylic acid derivatives in order to better define structure-activity relationships that could explain their anti-
invasive activity. Particular attention was paid to the replacement of the oxygen atom included in the exocyclic 
ester function in the 3-position by a sulphur atom (thioesters) or by a nitrogen atom (amides) with or without a 
methyl group. The importance of the nature and the size of the substituent in the 6-position was also examined. 
Among them, the replacement of the metabolically labile ester function (acetoxymethyl moiety) in the 6-position 
by a more stable amide function (acetamidomethyl moiety) was investigated. In these series, the presence of a 
halogen atom in the meta position of the phenyl ring in the 3 -position (preferably a chlorine or a bromine atom) 
was maintained like in the structure of the lead compounds 1 and 2. 
 
Fig. 1. Chemical structure of coumarins known to exert anti-cancer activity. 
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Fig. 2. Structure of the anti-angiogenic drug linomide (8) in two different conformations. The 'cis' conformation 
of linomide (8') can be superimposed to the low energy 'cis' conformation of the coumarinic aryl esters (9') but 
not to the stable conformation of the coumarinic aryl amides (10) characterised by the existence of a strong 




Scheme 1 illustrates the synthetic pathway giving access to the coumarinic derivatives characterised by the 
introduction of a thioester function or an amide function in the 3-position. 
Compound 12 obtained from 11 by acetylation was converted into the corresponding acid chloride 13 as 
previously described [21,23]. The acyl chloride intermediate 13 then reacted with appropriate thiophenols and 
anilines to provide the thioesters 14, the secondary amides 15 and the tertiary amides 16 (Scheme 1). 
Starting from 11, acylation, with the appropriate anhydride, of the exocyclic OH function located on the 
hydroxymethyl group in the 6-position led to the acid esters 17 (Scheme 2). The latter intermediates were 
converted into the acyl chlorides 18 and then into the 3-bromophenyl esters 19 after reaction of 18 with 3-
bromophenol in the presence of a base (Scheme 2). 
Examples of coumarin derivatives with a nitro group in the 6-position were obtained according to Scheme 3. The 
commercially available 5-nitrosalicylaldehyde 20 was converted into ethyl 6-nitrocoumarin-3-carboxylate 21 
after reaction with ethyl malonate in the 'Knoevenaegel' reaction conditions. The ethyl ester 21 was hydrolyzed 
to provide the corresponding carboxylic acid 22. The latter was converted into the acyl chloride 23 which then 
reacted with the appropriate metahalophenol to provide the aryl esters 24. 
Finally, 6-aminomethyl- (27) and 6-acetamidomethyl-substituted (28) halophenyl esters of coumarin-3-
carboxylic acid were obtained according to Scheme 4. Compounds 25 previously described [23] reacted with 
hexamethylenetetramine to give the hexaminium salts 26. The 'Delepine' reaction conditions of hydrolysis were 
then used to convert the hexaminium salts into the corresponding primary amines 27. In the last step, acetylation 
of the amine function of 27 provided the corresponding acetamides 28. 
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Scheme 1.   Reagents: (i) Ac2O; (ii) SOCl2; (iii) ArSH, pyridine, dioxane; (iv) ArNH2, pyridine, dioxane; and (v) 
ArNHCH3, pyridine, dioxane. 
 
 
Scheme 2.   Reagents: (i) (RCO)2O; (ii) SOCl2; and (iii) 3-bromophenol, pyridine, dioxane. 
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Scheme 3.   Reagents: (i) diethyl malonate, piperidine, HOAc, EtOH; (ii) NaOH, H2O; (iii) SOCl2; and (iv) 3-
halophenol, pyridine, dioxane. 
 
 
Scheme 4.   Reagents: (i) hexamethylenetetramine, CHCl3; (ii) HCl, EtOH; and (iii) Ac2O, TEA, DMF. 
 
 
3. Results and discussion 
The new synthetic coumarins were examined in a 'Boyden chamber' invasion assay using HT 1080 fibrosarcoma 
cells in order to determine their potency in reducing the invasive behaviour of tumour cells [10]. The assay 
consists in measuring the ability of cells treated or not with the coumarinic derivatives tested at different 
concentrations to pass through type IV collagen-coated Transwell cell culture inserts (chemoinvasion assay). 
Cell invasion in the absence of coumarin derivative was considered as 100%. Results were compared to those 
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observed with a reference compound, GI 129471 (29, Fig. 3), a well-known broad-spectrum hydroxamate-type 
MMP inhibitor, used at 1 µM concentration, previously reported to be active in this model [10], and also 
compared to those obtained with the active coumarin derivatives 1 and 2 at three different concentrations: 0.1, 1 
and 10 µM. The activity at 1 µM of another synthetic MMP inhibitor, Ro 28-2653 (30, Fig. 3), an MMP-
2/MMP-9/MT-MMP-selective inhibitor, was also examined in the same chemoinvasion assay. 
 
Fig. 3. Chemical structure of two synthetic MMP inhibitors. 
 
 
Table 1 indicates that GI 129471 at 1 µM concentration was able to reduce by 62% the invasion of HT 1080 cells 
through type IV collagen. The other MMP inhibitor, Ro 28-2653, was found to be equally active to GI 129471 at 
1 µM. As previously reported, the bromo-substituted coumarin 2 giving 78% inhibition of cell invasion at 1 µM 
concentration was found to be more potent than the reference compound GI 129471, whereas the corresponding 
chloro-substituted analogue 1 was also active (51% inhibition of cell invasion at 1 µM) but less potent than the 
two formers [10]. 
Replacement of the oxygen atom of the exocyclic ester function in the 3-position by a sulphur atom (thioesters 
14a-c) resulted in a significant reduction of the ability of the drugs at inhibiting HT 1080 cell invasion through 
type IV collagen (compare the results obtained with 14b versus 1 and with 14c versus 2 at 1 and 10 µM). The 
absence of a halogen atom on the phenyl ring (see 14a) appeared to be unfavourable for the anti-invasive activity 
compared to halo-substituted compounds. 
The secondary amide 15a, resulting from the replacement of the oxygen atom of the exocyclic ester function of 
compound 1 by a NH group, was also found to be less active than 1 giving 33% inhibition of cell invasion at 1 
µM (versus 51% for 1) and 57% inhibition at 10 µM (versus 94% for 1). Such an effect could be explained by 
the fact that amides such as 15a may adopt a stable conformation in which a strong hydrogen bond interaction is 
established between the NH group and the lactonic carbonyl oxygen. By contrast, a greater conformational 
freedom is given to esters such as 1 and 2 which may adopt the putative favourable 'cis' conformation of the two 
carbonyl groups (see structure 9', Fig. 2). 
Surprisingly, compound 16b, the N-methyl derivative of 15a, was not very potent in the cell invasion assay, 
although the presence of a methyl group on the nitrogen atom warranted the absence of intra-molecular H-bond 
interaction with the lactonic carbonyl group. 
Table 1 also reports examples of analogues of the lead compound 2 for which the size and the branching of the 
alkyl chain on the acyloxymethyl group in the 6-position were modified. An increase in the size of the chain 
conducted to a progressive reduction of drug efficacy in inhibiting cell invasion. Interestingly, the branching of 
the alkyl chain with 19f (isopropyl) and 19g (tert-butyl) led to a less pronounced decrease of their biological 
activity compared to compound 2. Marked differences can be seen especially at 0.1 µM between the linear (19a-
19e) and the branched (19f-19g) 6-acyloxymethylcoumarin derivatives. 
The replacement of the acetyloxymethyl substituent in the 6-position of the coumarin ring of compound 1 or 
compound 2 by another substituent such as a nitro, an aminomethyl and an acetamidomethyl moiety was also 
examined. The biological results obtained in the 'Boyden chamber' assay with the compounds are reported in 
Table 2. The efficacy of the new coumarin derivatives in this test was compared to that of previously reported 
coumarins bearing a hydrogen atom (31), a methyl (32), a chloromethyl (25c) and an acetoxymethyl group (1 
and 2) in the 6-position [10]. 
Compared to 2, the replacement of the acetoxymethyl moiety in the 6-position by a nitro group gave rise to a less 
potent bromophenyl ester 24d when tested at 1 µM in the chemoinvasion assay, but the latter was the most 
potent compound among the 6-nitro-substituted coumarins (24a-e) indicating that the presence of a bromine 
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atom on the phenyl ring was the best choice of halogen atom in this series of coumarinic compounds. 
In the case of the 6-aminomethyl-substituted coumarins (27a-e), the bromophenyl ester 27d was less potent than 
the corresponding bromophenyl reference compound 2. Interestingly, the best choice of halogen atom on the 
phenyl ring was the most bulky and lipophilic iodine atom giving rise to the very potent compound 27e. Thus, 
except in the case of an iodine atom, another halogen atom on the phenyl ring didn't improve the activity. 
When the amino group is acetylated, the resulting compounds (28a-e) are the amide isosteres of compounds 1 
and 2. The iodophenyl ester 28e was found to be as potent as the reference compound 2 at a 1 µM concentration. 
The chloro-substituted amide compound 28c expressed a better activity at 1 µM than its corresponding ester 
isostere 1 in the chemoinvasion assay, while the bromo-substituted amide 28d was found to be slightly less 
potent than its ester analogue 2 at 0.1 and 1 µM. It may be concluded that the ester function sensitive to 
metabolic hydrolysis can be advantageously replaced by a more stable amide function without dramatic decrease 
of biological activity. 
 
Table 1 Effect of the new coumarin derivatives 14a-c, 15a, 16a-c and 19a-g at 0.1, 1 and 10 µM on HT 1080 
fibrosarcoma cell invasion ('Boyden chamber' chemoinvasion assay) compared to the coumarins 1 and 2 and the 
MMP inhibitors GI 129471 and Ro 28-2653 
 
Compound no. X Y R 0.1 µMa 1 µMa 10 µMa
14a S H -CH3 89.45 ± 5.78 83.45 ± 6.45 73.84 ± 5.45 
14b S 3-Cl -CH3 76.54 ± 5.54 65.84 ± 3.75 61.86 ± 4.48 
14c s 3-Br -CH3 79.58 ±7.84 70.86 ± 6.14 67.84 ± 5.58 
15a NH 3-Cl -CH3 79.55 ± 2.04 66.85 ± 6.14 42.75 ± 3.58 
16a NCH3 2-Cl -CH3 n.d.b 62.78 ± 5.16 n.d. 
16b NCH3 3-Cl -CH3 n.d. 82.56 ± 6.86 n.d. 
16c NCH3 4-Cl -CH3 n.d. 98.56 ± 5.12 n.d. 
19a O 3-Br -CH2CH3 84.36 ± 2.36 40.23 ± 2.35 21.32 ± 1.96 
19b O 3-Br -(CH2)2CH3 88.55 ± 2.88 50.47 ± 2.89 24.67 ± 2.23 
19c O 3-Br -(CH2)3CH3 92.36 ± 4.42 63.25 ± 1.61 32.26 ± 0.42 
19d O 3-Br -(CH2)4CH3 94.25 ± 2.96 59.32 ± 3.54 33.94 ± 4.01 
19e O 3-Br -(CH2)5CH3 89.36 ± 3.25 55.56 ± 2.89 35.96 ± 6.85 
19f O 3-Br -CH(CH3)2 54.36 ± 4.23 37.80 ± 1.64 21.07 ± 0.45 
19g O 3-Br -C(CH3)3 65.24 ± 5.63 48.21 ± 8.32 23.64 ± 3.46 
1c O 3-Cl -CH3 95.20 ± 10.54 49.11 ± 7.64 6.17 ± 3.72 
2c O 3-Br -CH3 39.47 ± 2.04 21.81 ± 7.14 11.77 ± 1.24 
GI 129471    n.d. 38.45 ± 2.36 n.d. 
Ro 28-2653    n.d. 41.60 ± 4.35 n.d. 
a Results are expressed as the number of migrated cells in % of control (100%) corresponding to the assay in the absence of tested compound 
(mean ± s.d., n ≥ 3). 
b n.d.: Not determined.  













Table 2 Effect of the new coumarin derivatives 24a-e, 27a-e and 28a-e on HT 1080 fibrosarcoma cell invasion 
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('Boyden chamber' chemoinvasion assay) compared to coumarins 1, 2, 31, 32 and 25c and the MMP inhibitor GI 
129471 
 
Compound no. X Y 0.1 µMa 1 µMa 10 µMa
24a -NO2 -H n.db 76.68 ± 5.64 n.d. 
24b -NO2 -F n.d. 53.56 ± 2.04 n.d. 
24c -NO2 -Cl n.d. 65.78 ± 5.16 n.d. 
24d -NO2 -Br n.d. 35.22 ± 4.13 n.d. 
24e -NO2 -I n.d. 63.58 ± 5.12 n.d. 
27a -CH2NH2 -H n.d. 85.53 ± 6.54 n.d. 
27b -CH2NH2 -F n.d. 45.25 ± 7.14 n.d. 
27c -CH2NH2 -Cl n.d. 86.56 ± 4.13 n.d. 
27d -CH2NH2 -Br 88.26 ± 5.12 79.25 ± 7.15 63.58 ± 6.32 
27e -CH2NH2 -I n.d. 25.34 ± 7.15 n.d. 
28a -CH2NHCOCH3 -H n.d. 63.45 ± 5.54 n.d. 
28b -CH2NHCOCH3 -F n.d. 65.58 ± 1.24 n.d. 
28c -CH2NHCOCH3 -Cl n.d. 36.58 ± 0.86 n.d. 
28d -CH2NHCOCH3 -Br 34.38 ± 3.44 36.94 ± 5.34 27.14 ± 4.50 
28e -CH2NHCOCH3 -I n.d. 23.47 ± 6.32 n.d. 
31c -H -Cl 52.40 ± 11.13 45.50 ± 9.97 35.65 ± 6.94 
32c -CH3 -Cl 81.50 ± 5.12 52.49 ± 1.44 27.62 ± 1.50 
25cc -CH2Cl -Cl 98.35 ± 5.47 79.76 ± 8.71 67.00 ± 7.73 
1 -CH2OCOCH3 -Cl 95.20 ± 10.54 49.11 ± 7.64 6.17 ± 3.72 
2 -CH2OCOCH3 -Br 39.47 ± 2.04 21.81 ± 7.14 11.77 ± 1.24 
GI 129471   n.d. 38.45 ± 2.36 n.d. 
a Results are expressed as the number of migrated cells in % of control (100%) corresponding to the assay in the absence of tested compound 
(mean ± s.d., n ≥ 3). 
b n.d.: Not determined.  
c Published results (Ref. [10]). 
 
4. Conclusion 
The present work aimed at describing new examples of coumarin-3-carboxylic acid derivatives structurally 
related to lead coumarins 1 and 2 expressing anti-invasive activity in vitro and anti-tumoral effect in vivo. 
Among the different chemical modifications examined, the replacement of the ester function in the 6-position of 
1 and 2 by an amide function was allowed without loss of potency in the 'Boyden chamber' chemoinvasion assay 
with HT 1080 fibrosarcoma cells. By contrast, an aryl ester function in the 3-position was strongly recommended 
since its replacement by a thioester or an amide function was responsible for a significant decrease of the anti-
invasive activity. 
The increase of the size of the alkyl chain located on the acyloxymethyl moiety in the 6-position reduced the 
anti-invasive activity, although a short branched chain such as an isopropyl or a tert-butyl chain was allowed 
without markedly reducing the activity in the chemoinvasion assay. 
5. Experimental protocols 
5.1. Chemistry 
Melting points were determined with a Büchi-Tottoli capillary apparatus and are uncorrected. IR spectra were 
recorded as KBr pellets on a Perkin—Elmer 1000FTIR spectrophotometer. The 1H NMR spectra were recorded 
on a Bruker AW-80 (80 MHz) or a Bruker Avance (500 MHz) instrument using d6-DMSO as the solvent with 
TMS as an internal standard; chemical shifts are reported in δ values (ppm) relative to that of internal TMS. The 
abbreviations s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, and b = broad are used 
throughout. Elemental analysis (C, H, N, and S) was realized on a Carlo-Erba EA 1108-elemental analyser and 
was within ±0.4% of the theoretical values. All reactions were routinely checked by TLC on silica gel Merck 60 
F254. 
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GI129471 was synthesized by Roche Diagnostics according to the PCT Patent Applications WO 90/05719. Ro 
28-2653 was obtained according to a synthetic route described in the literature [24]. 
6-Hydroxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (11), 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-
carboxylic acid (12), phenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25a), 3-fluorophenyl 6-
chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25b), 3-chlorophenyl 6-chloromethyl-2-oxo-2H-1-
benzopyran-3-carboxylate (25c), 3-bromophenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25d) 
and 3-iodophenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25e) were obtained according to 
previously described procedures [21,23]. 
5.2. General procedure for the preparation of the 6-acyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acids 
(17a-g) 
Three grams of 6-hydroxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (11) were refluxed with the 
appropriate anhydride for 3 h. After cooling, 200 mL of distilled water were added and the suspension was 
stirred overnight. The resulting precipitate was collected by filtration, washed with distilled water and dried. The 
crude product was then crystallized in the appropriate solvent (yields: 60-80%). 
5.2.1. 6-Propionoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17a) 
The title compound was obtained as described above after the reaction of 11 with propionic anhydride (30 mL). 
The crude product was crystallized in CHCl3:petroleum ether 40-60°C: mp 174-176.5°C; IR 3055 (C-H arom), 
1754 (C=O ester), 1741 (C=O lactone), 1689 (C=O carboxylic acid), 1622, 1577, 1414, 1378 cm-1; 1H NMR 
1.18 (t, 3H, CH3), 2.42 (q, 2H, CH2CH3), 5.21 (s, 2H, CH2OCOC2H5), 7.50 (d, 1H, 8-H), 7.75 (s, 1H, 5-H), 7.77 
(d, 1H, 7-H), 8.94 (s, 1H, 4-H). Anal. C14H12O6 (C, H). 
5.2.2.  6-Butyryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17b) 
The title compound was obtained as described above after the reaction of 11 with butyric anhydride (30 mL). 
The crude product was crystallized in CH3CN:water: mp 146-147.5°C; IR 3046 (C-H arom), 1740 (C=O lactone 
and ester), 1692 (C=O carboxylic acid), 1626, 1581, 1415, 1372 cm-1; 1H NMR 0.96 (t, 3H, CH3), 1.68 (m, 2H, 
CH2CH2CH3), 2.37 (t, 2H, CH2CH2CH3), 5.19 (s, 2H, CH2OCO(CH2)2CH3), 7.49 (d, 1H, 8-H), 7.71 (d, 1H, 7-
H), 7.75 (s, 1H, 5-H), 8.94 (s, 1H, 4-H). Anal. C15H14O6 (C, H). 
5.2.3.  6-Valeryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17c) 
The title compound was obtained as described above after the reaction of 11 with valeric anhydride (30 mL). The 
crude product was crystallized in CHCl3:diisopropylether: mp 108.5-109°C; IR 3055 (C-H arom), 1741 (C=O 
lactone and ester), 1689 (C=O carboxylic acid), 1624, 1578, 1409, 1375 cm-1; 1H NMR 0.88 (t, 3H, CH3), 1.42 
(m, 2H, CH2CH3), 1.55 (m, 2H, CH2CH2CH3), 2.35 (t, 2H, CH2CH2CH2CH3), 5.20 (s, 2H, CH2OCO(CH2)3CH3), 
7.50 (d, 1H, 8-H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 8.96 (s, 1H, 4-H). Anal. C16H16O6 (C, H). 
5.2.4.  6-Hexanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17d) 
The title compound was obtained as described above after the reaction of 11 with hexanoic anhydride (20 mL). 
The crude product was crystallized in CH3CN:water: mp 103-105.5°C; IR 3052 (C-H arom), 1740 (C=O lactone 
& ester), 1697 (C=O carboxylic acid), 1625, 1579, 1414, 1375 cm-1; 1H NMR 0.85 (t, 3H, CH3), 1.24 (m, 4H, 
CH2CH2CH3), 1.56 (m, 2H, CH2(CH2)2CH3), 2.35 (t, 2H, CH2(CH2)3CH3), 5.20 (s, 2H, CH2OCO(CH2)4CH3), 
7.54 (d, 1H, 8-H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.02 (s, 1H, 4-H). Anal. C17H18O6 (C, H). 
5.2.5.  6-Heptanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17e) 
The title compound was obtained as described above after the reaction of 11 with heptanoic anhydride (35 mL). 
The crude product was crystallized in CHCl3:petroleum ether 40-60°C: mp 102-102.5°C; IR 3055 (C-H arom), 
1743 (C=O lactone and ester), 1690 (C=O carboxylic acid), 1624, 1578, 1410, 1375 cm-1; 1H NMR 0.88 (t, 3H, 
CH3), 1.24 (m, 6H, (CH2)3CH3), 1.55 (m, 2H, CH2(CH2)3CH3), 2.38 (t, 2H, CH2(CH2)4CH3), 5.20 (s, 2H, 
CH2OCO (CH2)5CH3), 7.46 (d, 1H, 8-H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.04 (s, 1H, 4-H). Anal. C18H20O6 
(C, H). 
5.2.6.   6-Dimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17f) 
The title compound was obtained as described above after the reaction of 11 with isobutyric anhydride (30 mL). 
The crude product was crystallized in CHCl3:petroleum ether 40-60°C: mp 134-135°C; IR 3049 (C-H arom), 
1753 (C=O ester), 1726 (C=O lactone), 1684 (C=O carboxylic acid), 1620, 1576, 1416, 1386 cm-1; 1H NMR 
1.20 (d, 6H, (CH3)2), 2.63 (q, 1H, CH), 5.20 (s, 2H, CH2), 7.49 (d, 1H, 8-H), 7.74 (s, 1H, 5-H), 7.76 (d, 1H, 7-H), 
8.94 (s, 1H, 4-H). Anal. C15H14O6 (C, H). 
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5.2.7.  6-Trimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (17g) 
The title compound was obtained as described above after the reaction of 11 with pivaloic anhydride (30 mL). 
The crude product was crystallized in CHCl3:petroleum ether 40-60 °C: mp 136-137.5°C; IR 3044 (C-H arom), 
2969 (C-H aliph), 1743 (C=O lactone and ester), 1674 (C=O carboxylic acid), 1620, 1575, 1417, 1157 cm-1; 1H 
NMR 1.24 (s, 9H, (CH3)3), 5.20 (s, 2H, CH2), 7.50 (d, 1H, 8-H), 7.74 (s, 1H, 5-H), 7.76 (d, 1H, 7-H), 8.95 (s, 
1H, 4-H). Anal. C16H16O6 (C, H). 
5.2.8.  Ethyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (21) 
A mixture of 5-nitro-salicylaldehyde (20) (1 g, 5.98 mmol), diethyl malonate (1.05 g, 6.59 mmol), piperidine 
(0.076 mL) and acetic acid (0.03 mL) in ethanol (4 mL) was heated under reflux for 18 h. The resulting 
precipitate was collected by filtration and washed with ethanol. The crude product was suspended in methanol, 
collected by filtration, washed with methanol and dried (yield: 64%): mp 195.5-196.5; IR 3078, 3056 (C-H 
arom), 1779 (C=O ester), 1757 (C=O lactone), 1692, 1619, 1570, 1528, 1348, 1256 cm-1; 1H NMR 1.33 (t, 3H, 
CH3), 4.33 (q, 2H, CH2), 7.66 (d, 1H, 8-H), 8.51 (d, 1H, 7-H), 8.93-8.94 (m, 2H, 4-H, 5-H). Anal. C12H9NO6 (C, 
H, N). 
5.2.9.  6-Nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (22)  
The suspension of ethyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (21) (5 g, 18.9 mmol) in 10% aqueous 
NaOH (150 mL) was heated under reflux for 30 min. After cooling, pH was adjusted to 1 by 12 N HCl, while 
stirring over an ice bath. The resulting precipitate was collected by filtration, washed with distilled water and 
crystallized in CH3CN (yield: 91%): mp 229.5-230°C; IR 3116, 3076 (C-H arom), 1723 (C=O lactone and 
carboxylic acid), 1617, 1536, 1523, 1354, 1233, 1208 cm-1; 1H NMR 7.65 (d, 1H, 8-H), 8.50 (d, 1H, 7-H), 8.90 
(s, 1H, 4-H), 8.91 (s, 1H, 5-H), 13.51 (s, 1H, COOH). Anal. C10H5NO6 (C, H, N). 
5.3. General procedure for the preparation of the thioesters (14), the secondary (15) and tertiary (16) amides of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid, the esters of 6-acyloxymethyl-2-oxo-2H-1-
benzopyran-3-carboxylic acid (19) and 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (24) 
The appropriate carboxylic acid (1 g) was refluxed in thionyl chloride (10 mL) for 3 h. The resulting solution 
was concentrated to dryness under reduced pressure and the residue was dispersed in dry toluene (10 mL). The 
solvent was eliminated under reduced pressure. Dispersion in dry toluene and solvent elimination was repeated 
twice. The residue was dispersed in anhydrous dioxane (3 mL) and added with stirring to a solution of the 
appropriate phenol, thiophenol or aniline and anhydrous pyridine in anhydrous dioxane. The progress of the 
reaction was followed by TLC. Yields are usually comprised between 50% and 80%. 
5.3.1. S-Phenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carbothioate (14a) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with thiophenol (0.49 g, 4.5 
mmol) and pyridine (1 mL, 12.5 mmol). After stirring overnight at room temperature, the solvents were 
eliminated by distillation under reduced pressure. The residue was dissolved in warm ethyl acetate and the 
solution was treated with charcoal. After reducing the volume of the filtrate, precipitation was obtained by 
addition of petroleum ether 40-60°C. The crude product was crystallized twice in ethyl acetate: mp 140.5-142°C; 
IR 3047 (C-H arom), 1729 (C=O lactone and ester), 1662 (C=O thioester), 1568, 1182 cm-1; 1H NMR 2.09 (s, 
3H, CH3), 5.16 (s, 2H, CH2), 7.54-7.53 (m, 6H, 8-H, C6H5), 7.79 (d, 1H, 7-H), 8.01 (s, 1H, 5-H), 8.81 (s, 1H, 4-
H). Anal. C19H14O5S (C, H, S). 
5.3.2.  S-3-Chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carbothioate (14b) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8mmol) with 3-chlorothiophenol (0.65 g, 
4.5 mmol) and pyridine (1 mL, 12.5 mmol). After stirring overnight at room temperature, the solvents were 
eliminated by distillation under reduced pressure. The residue was dissolved in warm ethyl acetate and the 
solution was treated with charcoal. After reducing the volume of the filtrate, precipitation was obtained by 
addition of petroleum ether 40-60°C. The crude product was crystallized twice in ethyl acetate: mp 135.5-137°C; 
IR 3066 (C-H arom), 1738 (C=O ester), 1728 (C=O lactone),  1656 (C=O thioester),  1569,  1181cm-1;  1H NMR 
2.08  (s, 3H, CH3), 5.16 (s, 2H, CH2), 7.49 (d, 1H, 4'-H), 7.53-7.55 (m, 2H, 8-H, 5'-H), 7.59-7.61 (m, 2'-H, 6'-H), 
7.80 (d, 1H, 7-H), 8.02 (s,1H, 5-H), 8.83 (s, 1H, 4-H). Anal. C19H13O5SCl (C, H, S). 
5.3.3.  S-3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carbothioate (14c) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with 3-bromothiophenol (0.85 g, 
4.5 mmol) and pyridine (1 mL, 12.5 mmol). After stirring overnight at room temperature, the solvents were 
Published in: European Journal of Medicinal Chemistry (2008), vol. 43, iss. 12, pp. 2735-2750. 
Status : Postprint (Author’s version) 
 
eliminated by distillation under reduced pressure. The residue was dissolved in warm ethyl acetate and the 
solution was treated with charcoal. After reducing the volume of the filtrate, precipitation was obtained by 
addition of petroleum ether 40-60°C. The crude product was crystallized twice in ethyl acetate: mp 129.5-
132.5°C; IR 3062 (C-H arom), 1736 (C=O ester), 1725 (C=O lactone),  1657 (C=O thioester),  1568,  1181cm-1;  
1H NMR 2.09  (s, 3H, CH3), 5.16 (s, 2H, CH2), 7.48 (d, 1H, 6'-H), 7.52-7.56 (m, 2H, 8-H, 5'-H), 7.72-7.74 (m, 
2'-H, 4'-H), 7.80 (d, 1H, 7-H), 8.02 (s,lH, 5-H), 8.83 (s, 1H, 4-H). Anal. C19H13O5SBr (C, H, S). 
5.3.4.  N-3-Chlorophenyl 6-acetoxymethyl-2-oxo-2H-1 -benzopyran-3-carboxamide (15a) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with 3-chloroaniline (0.63 g, 5 
mmol) and pyridine (1 mL, 12.5 mmol). After 6 h at room temperature, the resulting precipitate was collected by 
filtration and washed with dioxane. The crude product was dissolved in CHCl3 and treated with charcoal, then 
cyclohexane was added and the resulting precipitate was collected by filtration and dried: mp 187-190°C; IR 
3263, 3124 (C-H arom), 1742 (C=O lactone and ester), 1699 (C=O amide), 1617, 1591, 1575, 1541, 1427, 1240 
cm-1; 1H NMR 2.10 (s, 3H, CH3), 5.17 (s, 2H, CH2), 7.21 (d, 1H, 8-H), 7.42 (t, 1H, 5'-H), 7.56-7.59 (m, 2H, 8-H, 
4'-H), 7.77 (d, 1H, 7-H), 7.99 (d, 2H, 2'H, 6'-H), 8.89 (s, 1H, 4-H), 10.75 (s,1H, NH). Anal. C19H14O5NCl (C, H, 
N). 
5.3.5.  N-methyl-N-(2-chlorophenyl)-6-acetoxymethyl-2-oxo-2H-1-benzopyran-3 -carboxamide (16a) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with 2-chloro-N-methylaniline 
(0.7 g, 5 mmol) and pyridine (1 mL, 12.5 mmol). After 6 h at room temperature, water was added and the 
mixture was cooled on an ice bath, then the resulting precipitate was collected by filtration and dried: mp 119-
121°C; IR 3061, 2938 (C-H arom), 1732 (C=O lactone and ester), 1648 (C=O amide), 1623, 1580, 1486, 1233 
cm-1; 1H NMR 2.09 (s, 3H, CH3), 3.24 (s, 3H, NCH3), 5.09 (s, 2H, CH2), 7.28-7.33 (m, 2H, 4'-H, 8-H), 7.46-7.49 
(m, 3H, 3'-H, 5'-H, 7-H), 7.59 (d, 1H, 6'-H), 7.73 (s, 1H, 5-H), 8.23 (s, 1H, 4-H). Anal. C20H16O5NCl (C, H, N). 
5.3.6. N-Methyl-N-(3-chlorophenyl)-6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxamide (16b) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with 3-chloro-N-methylaniline 
(0.7 g, 5 mmol) and pyridine (1 mL, 12.5 mmol). After 8 h at room temperature, the resulting precipitate was 
collected by filtration and washed with dioxane. The crude product was crystallized twice in methanol: mp 106-
108°C; IR 3062, 2963 (C-H arom), 1729 (C=O lactone and ester), 1648 (C=O amide), 1623, 1591, 1580, 1481, 
1230 cm-1; 1H NMR 2.07 (s, 3H, CH3), 3.33 (s, 3H, NCH3), 5.12 (s, 2H, CH2), 7.25 (m, 1H, 4'-H),7.30 (m, 2H, 
5'-H, 8-H), 7.37 (m, 1H, 7-H), 7.47 (s, 1H, 5-H), 7.62 (d, 1H, 6'-H), 7.73 (s, 1H, 2'-H), 8.26 (s, 1H, 4-H). Anal. 
C20H16O5NCl (C, H, N). 
5.3.7. N-Methyl-N-(4-chlorophenyl)-6-acetoxymethyl-2-oxo-2H-1-benzopyran-3 -carboxamide (16c) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (13) (~3.8 mmol) with 4-chloro-N-methylaniline 
(0.7 g, 5 mmol) and pyridine (1 mL, 12.5 mmol). After 6 h at room temperature, water was added and the 
mixture was cooled on an ice bath, then the resulting precipitate was collected by filtration and dried. The crude 
product was crystallized in methanol: mp 117-119°C; IR 3054, 2951 (C-H arom), 1744 (C=O ester), 1731 (C=O 
lactone), 1649 (C=O amide), 1622, 1580, 1494, 1224 cm-1; 1H NMR 2.06 (s, 3H, CH3), 3.33 (s, 3H, NCH3), 5.11 
(s, 2H, CH2), 7.32-7.37 (m, 5H, 3'-H, 5'-H, 5-H, 7-H, 8-H), 7.62 (d, 1H, 6'-H), 7.71 (s, 1H, 2'-H), 8.24 (s, 1H, 4-
H). Anal. C20H16O5NCl (C, H, N). 
5.3.8.  3-Bromophenyl 6-propionoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19a) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-propionoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18a) (~3.5mmol) with 3-bromophenol (0.71 g, 
4 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. 
The resulting precipitate was collected by filtration and dried: mp 124-124.5°C; IR 3064 (C-H arom), 1775 and 
1737 (C=O esters), 1690 (C=O lactone), 1624, 1577, 1470, 1377, 1246 cm-1; 1H NMR 1.07 (t, 3H, CH3), 2.41 (q, 
2H, CH2CH3), 5.19 (s, 2H, CH2OCOC2H5), 7.33 (d, 1H, 6'-H), 7.46 (t, 1H, 5'-H), 7.50 (d, 1H, 8-H), 7.55 (d, 1H, 
4'-H), 7.60 (s, 1H, 2'-H), 7.88 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.09 (s, 1H, 4-H). Anal. C20H15BrO6 (C, H). 
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5.3.9.  3-Bromophenyl 6-butyryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19b) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-butyryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18b) (~3.3 mmol) with 3-bromophenol (0.7 g, 4 
mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by evaporation 
under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three times with 
0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The residue was 
then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. The resulting 
precipitate was collected by filtration and dried: mp 140.5°C; IR 3067 (C-H arom), 1736 (C=O esters), 1691 
(C=O lactone), 1628, 1579, 1471, 1367, 1247 cm-1; 1H NMR 0.89 (t, 3H, CH3), 1.58 (m, 2H, CH2CH3), 2.37 (t, 
2H, CH2CH2CH3), 5.19 (s, 2H, CH2OC-O(CH2)2CH3), 7.33 (d, 1H, 6'-H), 7.47 (t, 1H, 5'-H), 7.50 (d, 1H, 8-H), 
7.55 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.09 (s, 1H, 4-H). Anal. C21H17BrO6 
(C, H). 
5.3.10.  3-Bromophenyl 6-valeryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19c) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-valeryloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18c) (~3.1 mmol) with 3-bromophenol (0.65 g, 
3.7 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on ice bath. The 
resulting precipitate was collected by filtration and dried: mp 133-134.5°C; IR 3066 (C-H arom), 1736 (C=O 
esters), 1690 (C=O lactone), 1628, 1579, 1471, 1367, 1247 cm-1; 1H NMR 0.87 (t, 3H, CH3), 1.30 (m, 2H, 
CH2CH3), 1.54 (m, 2H, CH2CH2CH3), 2.38 (t, 2H, CH2CH2CH2CH3), 5.18 (s, 2H, CH2OCO(CH2)3CH3), 7.33 (d, 
1H, 6'-H), 7.47 (t, 1H, 5'-H), 7.50 (d, 1H, 8-H), 7.55 (d, 1H, 4'-H), 7.56 (s, 1H, 2'-H), 7.78 (d, 1H, 7-H), 7.97 (s, 
1H, 5-H), 9.09 (s, 1H, 4-H). Anal. C22H19BrO6 (C, H). 
5.3.11.  3-Bromophenyl 6-hexanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19d) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-hexanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18d) (~3 mmol) with 3-bromophenol (0.6 g, 
3.5 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. 
The resulting precipitate was collected by filtration and dried: mp 122.5-126°C; IR 3067 (C-H arom), 1732 
(C=O esters), 1692 (C=O lactone), 1628, 1580, 1471, 1367, 1247 cm-1; 1H NMR 0.85 (t, 3H, CH3), 1.26 (m, 4H, 
CH2CH2CH3), 1.56 (m, 2H, CH2(CH2)2CH3), 2.38 (t, 2H, CH2(CH2)3CH3), 5.18 (s, 2H, CH2OCO(CH2)4CH3), 
7.32 (d, 1H, 6'-H), 7.51 (t, 1H, 5'-H), 7.54 (d, 1H, 8-H), 7.56 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-H), 7.78 (d, 1H, 7-H), 
7.97 (s, 1H, 5-H), 9.09 (s, 1H, 4-H). Anal. C23H21BrO6 (C, H). 
5.3.12.  3-Bromophenyl 6-heptanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19e) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-heptanoyloxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18e) (~2.9 mmol) with 3-bromophenol (0.6 g, 
3.5 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. 
The resulting precipitate was collected by filtration and dried: mp 121-122.5°C; IR 3067 (C-H arom), 1734 
(C=O esters), 1689 (C=O lactone), 1628, 1580, 1471, 1367, 1247 cm-1; 1H NMR 0.84 (t, 3H, CH3), 1.24 (m, 6H, 
(CH2)3CH3),   1.55   (m,  2H,  CH2(CH2)3CH3),  2.38   (t,  2H, CH2(CH2)4CH3), 5.18 (s, 2H, 
CH2OCO(CH2)5CH3), 7.33 (d, 1H, 6'-H), 7.47 (t, 1H, 5'-H), 7.50 (d, 1H, 8-H), 7.56 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-
H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.09 (s, 1H, 4-H). Anal. C24H23BrO6 (C, H). 
5.3.13.  3-Bromophenyl 6-dimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19f) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-dimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18f) (~3.3 mmol) with 3-bromophenol 
(0.69 g, 4 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. 
The resulting precipitate was collected by filtration and dried: mp 152-153°C; IR 3067 (C-H arom), 1735 (C=O 
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esters and lactone), 1628, 1579, 1472, 1368, 1247 cm-1; 1H NMR 1.12 (d, 6H, CH3), 2.63 (q, 1H, CH), 5.18 (s, 
2H, CH2OCOCH(CH3)2), 7.33 (d, 1H, 6'-H), 7.46 (t, 1H, 5'-H), 7.50  (d, 1H, 8-H), 7.54 (d, 1H, 4'-H), 7.60 (s, 
1H, 2'-H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.10 (s, 1H, 4-H). Anal. C21H17BrO6 (C, H). 
5.3.14.  3-Bromophenyl 6-trimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate (19g) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-trimethylacetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylic acid (18g) (~3.1 mmol) with 3-bromophenol 
(0.6 g, 3.5 mmol) and pyridine (0.4 mL, 5 mmol). After 12 h at room temperature, the solvent was removed by 
evaporation under reduced pressure. The residue was dissolved in CHCl3 and the organic layer was washed three 
times with 0.1 N HCl, then dried over MgSO4 filtered, and evaporated to dryness under reduced pressure. The 
residue was then dissolved in warm methanol, treated with charcoal and crystallized by cooling on an ice bath. 
The resulting precipitate was collected by filtration and dried: mp 158-161°C; IR 3067 (C-H arom), 1732 (C=O 
esters), 1686 (C=O lactone), 1628, 1580, 1471, 1367, 1247 cm-1; 1H NMR 1.22 (s, 9H, CH3), 5.18 (s, 2H, 
CH2OCOC(CH3)3), 7.33 (d,  1H, 6'-H), 7.47 (t,  1H, 5'-H), 7.51   (d, 1H, 8-H), 7.55 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-
H), 7.78 (d, 1H, 7-H), 7.97 (s, 1H, 5-H), 9.12 (s, 1H, 4-H). Anal. C22H19BrO6 (C, H). 
5.3.15.  Phenyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (24a) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (23) ( ~4 mmol) with phenol (0.85 g, 9 mmol) and pyridine (1 
mL, 12.5 mmol). After 8 h at room temperature, the resulting precipitate was collected by filtration, washed with 
dioxane and left overnight at 30°C. The crude product was stirred in methanol and collected by filtration. It was 
then dissolved in warm DMF, treated with charcoal and filtered. The filtrate was kept at 4°C for 2 h. The 
resulting precipitate was collected, washed with DMF and methanol and dried for one night at 30°C. The crude 
product was suspended in methanol and collected by filtration (precipitate 1). Methanol was added to DMF 
filtrate and the resulting precipitate was collected by filtration, washed with methanol and pooled with precipitate 
1: mp 236.5-237.5°C; IR 3070 (C-H arom), 1775 (C=O ester), 1722 (C=O lactone), 1618, 1573, 1539, 1345, 
1256 cm-1; 1H NMR 7.28-7.36 (m, 3H, 2'-H, 4'-H, 6'-H), 7.49-7.52 (m, 2H, 3'-H, 5'-H), 7.71 (d, 1H, 8-H), 8.56 
(d, 1H, 7-H), 8.99 (s, 1H, 5-H), 9.25 (s, 1H, 4-H). Anal. C16H9NO6 (C, H, N). 
5.3.16.   3-Fluorophenyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (24b) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (23) (~4mmol) with 3-fluorophenol (1 g, 9 mmol) and 
pyridine (1 mL, 12.5 mmol). After 8 h at room temperature, the resulting precipitate was collected by filtration, 
washed with dioxane and kept overnight at 30°C. The crude product was stirred in methanol and collected by 
filtration. It was then dissolved in warm DMF, treated with charcoal and filtered. The filtrate was kept at 4°C for 
2 h. The resulting precipitate was collected by filtration, washed with DMF and methanol and dried for one night 
at 30°C. The crude product was suspended in methanol and collected by filtration (precipitate 1). Methanol was 
added to DMF filtrate and the resulting precipitate was collected by filtration, washed with methanol and pooled 
with precipitate 1: mp 226-226.5°C; IR 3086 (C-H arom), 1779 (C=O ester), 1721 (C=O lactone), 1621, 1572, 
1532, 1346, 1248 cm-1; 1H NMR 7.16-7.28 (m, 3H, 2'-H, 4'-H, 6'-H), 7.55 (t, 1H, 5'-H), 7.72 (d, 1H, 8-H), 8.56 
(d, 1H, 7-H), 8.99 (s, 1H, 5-H), 9.28 (s, 1H, 4-H). Anal. C16H8NO6F (C, H, N). 
5.3.17.  3-Chlorophenyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (24c) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (23) (~4mmol) with 3-chlorophenol (1.15 g, 9 mmol) and 
pyridine (1 mL, 12.5 mmol). After 8 h at room temperature, the resulting precipitate was collected by filtration, 
washed with dioxane and left overnight at 30°C. The crude product was stirred in methanol and collected by 
filtration. It was then dissolved in warm acetone (~150mL), treated with charcoal and filtered. The filtrate was 
kept at 4°C for 2 h and the resulting precipitate was collected by filtration, washed with cold acetone and dried: 
mp 245.5-246°C; IR 3075 (C-H arom), 1770 (C=O ester), 1723 (C=O lactone), 1620, 1572, 1541, 1347, 1248 
cm-1; 1H NMR 7.31 (d, 1H, 6'-H), 7.45 (d,  1H, 4'-H), 7.48 (s,  1H, 2'-H), 7.55 (t,  1H, 5'-H), 7.72 (d, 1H, 8-H), 
8.57 (d, 1H, 7-H), 8.99 (s, 1H, 5-H), 9.27 (s, 1H, 4-H). Anal. C16H8NO6C1 (C, H, N). 
5.3.18.   3-Bromophenyl 6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (24d) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-nitro-2-oxo-2H-1 -benzopyran-3-carboxylic acid (23) ( ~4 mmol) with 3-bromophenol (1.56 g, 9 mmol) and 
pyridine (1 mL, 12.5 mmol). After 4 h at room temperature, the resulting precipitate was collected by filtration, 
washed with dioxane and kept overnight at 30°C. The crude product was stirred in methanol and collected by 
filtration. It was then dissolved in warm DMF, treated with charcoal and filtered. The filtrate was kept at 4°C for 
2 h. The resulting precipitate was collected by filtration, washed with cold DMF and dried for one night at 30°C. 
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The crude product was dissolved in warm dioxane and treated with charcoal. The filtrate was cooled and the 
resulting precipitate was collected by filtration, washed with dioxane and water: mp 268-270°C; IR 3070 (C-H 
arom), 1772 (C=O ester), 1719 (C=O lactone), 1618, 1572, 1537, 1346, 1248 cm-1; 1H NMR 7.34 (d, 1H, 6'-H), 
7.48 (t, 1H, 5'-H), 7.57 (d, 1H, 4'-H), 7.61 (s, 1H, 2'-H), 7.71 (d, 1H, 8-H), 8.57 (d, 1H, 7-H), 8.98 (d, 1H, 5-H), 
9.26 (s, 1H, 4-H). Anal. C16H8NO6Br (C, H, N). 
5.3.19.     3-Iodophenyl    6-nitro-2-oxo-2H-1-benzopyran-3-carboxylate (24e) 
The title compound was obtained as described in the general procedure after the reaction of the acyl chloride of 
6-nitro-2-oxo-2H-1-benzopyran-3-carboxylic acid (23) (~4 mmol) with 3-iodophenol (1.98 g, 9 mmol) and 
pyridine (1 mL, 12.5 mmol). After 8 h at room temperature, the resulting precipitate was collected by filtration, 
washed with dioxane and kept overnight at 30°C. The crude product was stirred in methanol and collected by 
filtration. It was then dissolved in warm DMF, treated with charcoal and filtered. The filtrate was kept at 4°C for 
2 h. The resulting precipitate was collected by filtration, washed with DMF and methanol and dried for one night 
at 30°C: mp >260°C; IR 3068 (C-H arom), 1770 (C=O ester), 1720 (C=O lactone), 1616, 1570, 1532, 1344, 
1247 cm-1; 1H NMR 7.32 (d, 1H, 6'-H), 7.45 (t, 1H, 5'-H), 7.58 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-H), 7.71 (d, 1H, 8-
H), 8.57 (d, 1H, 7-H), 8.98 (d, 1H, 5-H), 9.28 (s, 1H, 4-H). Anal. C16H8NO6I (C, H, N). 
5.3.20.   Phenyl  6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27a) 
Hexamethylenetetramine (1.55 g, 11 mmol) was added to a solution of phenyl 6-chloromethyl-2-oxo-2H-1-
benzopyran-3-carboxylate (25a) (1.5 g, 3.2 mmol) in CHCl3 (45 mL). The mixture was heated under reflux for 
18 h. The resulting precipitate of phenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-
carboxylate chloride salt (26a) was collected by filtration and washed with warm CHCl3 (yield: 92%): mp 169-
171°C. Phenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate   chloride   salt (26a) 
(2.2 g, 4.8 mmol) and 12 N HCl (3.8 mL) in ethanol (16 mL) were heated under reflux for 90 min. After cooling, 
the resulting precipitate was collected by filtration, washed with ethanol and discarded. The filtrate was 
evaporated to dryness under reduced pressure and the residue was suspended in a 1% aqueous solution of 
NaHCO3. The resulting precipitate was collected by filtration and washed with water: mp >260°C; IR 3067 (C-H 
arom), 2885 (N+-H), 1775 (C=O ester), 1728 (C=O lactone), 1624, 1576, 1463, 1371, 1256, 1203 cm-1; 1H NMR 
3.39 (b, 3H, NH3+), 4.13 (s, 2H, CH2), 7.20-7.26 (m, 3H, 2'-H, 4'-H, 6'-H), 7.50-7.57 (m, 3H, 5'-H, 6'-H, 8-H), 
7.92 (d, 1H, 7-H), 7.99 (d, 1H, 5-H), 9.01 (s, 1H, 4-H). Anal. C17H13NO4·HCl (C, H, N). 
5.3.21.  3-Fluorophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27b) 
3-Fluorophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (26b) 
was obtained as described for 26a after the reaction of hexamethylenetetramine (1.15 g, 8.2 mmol) with 3-
fluorophenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25b) (1.2 g, 3.6 mmol). The resulting 
precipitate was collected by filtration and washed with cold CHCl3 (yield: 65%): mp 182°C. 3-fluorophenyl 6-
hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (26b) (1.6 g, 3.4 mmol) 
and 12 N HCl (2.7 mL) in ethanol (11 mL) were heated under reflux for 90 min. After cooling, the resulting 
precipitate was collected by filtration and washed with ethanol. The crude product was suspended in water 
(elimination of NH4Cl) and the resulting precipitate was collected by filtration and washed with water: mp 
>260°C; IR 2963; 2876 (N+-H), 1779 (C=O esters), 1722 (C=O lactone), 1626, 1580, 1485, 1376, 1248 cm-1; 1H 
NMR 3.37 (b, 3H, NH3+), 4.12 (s, 2H, CH2), 7.19-7.28 (m, 3H, 2'-H, 4'-H, 6'-H), 7.52-7.59 (m, 2H, 5'-H, 8-H), 
7.94 (d, 1H, 7-H), 8.04 (d, 1H, 5-H), 9.03 (s, 1H, 4-H). Anal. C17H12NO4F·HCl (C, H, N). 
5.3.22.  3-Chlorophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27c) 
3-Chlorophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (26c) 
was obtained as described for 26a after the reaction of hexamethylenetetramine (1.8 g, 12.8 mmol) with 3-
chlorophenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25c) (2 g, 5.7 mmol). The resulting 
precipitate was collected by filtration and washed with cold CHCl3: mp 210°C. The title compound was obtained 
as described for 27b after the reaction of 3-chlorophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-
benzopyran-3-carboxylate chloride salt (30c) (2 g, 4 mmol) with 12 N HCl (3.2 mL) in ethanol (13.3 mL) (yield: 
40%): mp >260°C; IR 2987, 2882 (N+-H), 1777 (C=O esters), 1720 (C=O lactone), 1626, 1579, 1488, 1382, 
1246 cm-1; 1H NMR 3.33 (b, 3H, NH3+), 4.12 (s, 2H, CH2), 7.30 (d, 1H, 6'-H), 7.43 (d, 1H, 4'-H), 7.48 (s, 1H, 
2'H), 7.52-7.59 (m, 2H, 5'-H, 8-H), 7.95 (d, 1H, 7-H), 8.04 (d, 1H, 5-H), 9.03 (s, 1H, 4-H). Anal. 
C17H12NO4Cl·HCl (C, H, N). 
5.3.23.  3-Bromophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27d) 
3-Bromophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (26d) 
was obtained as described for 26a after the reaction of hexamethylenetetramine (2.9 g, 20.7 mmol) with 3-
bromophenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate (25d) (4 g, 10 mmol). The resulting 
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precipitate was collected by filtration and washed with cold CHCl3: mp 174-178°C. The title compound was 
obtained as described for 27b after the reaction of 3-bromophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-
2H-1-benzopyran-3-carboxylate   chloride   salt   (26d)   (3 g, 5.6 mmol) with 12 N HCl (4.5 mL) in ethanol 
(18.7 mL) (yield: 65%): mp >260°C; IR 2986, 2885 (N+-H), 1776 (C=O esters), 1720 (C=O lactone), 1627, 
1580, 1469, 1381, 1246 cm-1; 1H NMR 3.36 (b, 3H, NH3+), 4.13 (s, 2H, CH2), 7.34 (d, 1H, 6'-H), 7.47 (t, 1H, 5'-
H), 7.55-7.61 (m, 3H, 2'-H, 4'-H, 8-H), 7.94 (d, 1H, 7-H), 8.03 (d, 1H, 5-H), 9.05 (s, 1H, 4-H). Anal. 
C17H12NO4Br·HCl (C, H, N). 
5.3.24.  3-Iodophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27e) 
3-Iodophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (26e) 
was obtained as described for 26a after the reaction of hexamethylenetetramine (1 g, 7 mmol) with 3-iodophenyl 
6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate   (25e)   (1.2 g, 2.7 mmol). The resulting precipitate was 
collected by filtration and washed with cold CHCl3 (yield: 70%): mp 171-175°C. The title compound was 
obtained as described for 27b after the reaction of 3-iodophenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-
1-benzopyran-3-carboxylate chloride salt (26e) (1.1 g, 1.9 mmol) with 12 N HCl (1.5 mL) in ethanol (6.3 mL): 
mp >260°C; IR 2987, 2890 (N+-H), 1778 (C=O esters), 1722 (C=O lactone), 1627, 1581, 1466, 1380, 1245 cm-1; 
1H NMR 3.38 (b, 3H, NH3+), 4.13 (s, 2H, CH2), 7.28-7.34 (m, 2H, 5'-H, 6'-H), 7.58 (d, 1H, 8-H), 7.70-7.74 (m, 
2H, 2'-H, 4'-H), 7.93 (d, 1H, 7-H), 8.03 (d, 1H, 5-H), 9.02 (s, 1H, 4-H). Anal. C17H12NO4I·HCl (C, H, N). 
5.3.25.  Phenyl 6-acetamidomethyl-2-oxo-2H-1-benzopyran-3-carboxylate (28a) 
Phenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27a) (0.1 g, 0.3 mmol) and TEA 
(0.06 ml, 0.45 mmol) were suspended in acetic anhydride (4 mL, 42.4 mmol). After 1 h, distilled water (50 mL) 
was added and the suspension was stirred at room temperature for 1 h. The resulting white precipitate was 
collected by filtration and washed with water. The crude product was then suspended in acetone for 15 min, then 
collected by filtration: mp >260°C; IR 3070 (C-H arom), 1774 (C=O ester), 1757 (C=O lactone), 1710 (C=O 
amide), 1651, 1621, 1574, 1491, 1380 cm-1; 1H NMR 1.91 (s, 3H, CH3), 4.32 (s, 2H, CH2), 7.29-7.35 (m, 3H, 2'-
H, 4'-H, 6'-H), 7.48 (d, 1H, 8-H), 7.50-7.51 (m, 2H, 3'-H, 5'-H), 7.67 (d, 1H, 7-H), 7.80 (s, 1H, 5-H), 8.45 (s, 1H, 
NH), 9.12 (s, 1H, 4-H). Anal. C19H15NO5 (C, H, N). 
5.3.26.  3-Fluorophenyl 6-acetamidomethyl-2-oxo-2H-1-benzopyran-3-carboxylate (28b) 
3-Fluorophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27b) (0.1 g, 0.3 mmol) and 
TEA (0.055 ml, 0.43 mmol) were suspended in acetic anhydride (4 mL, 42.4 mmol). After 1 h, distilled water 
(50 mL) was added and the suspension was stirred at room temperature for 1 h. The resulting white precipitate 
was collected by filtration and washed with water: mp 249-252°C; IR 3070 (C-H arom), 1775 (C=O ester), 1759 
(C=O lactone), 1712 (C=O amide), 1649, 1621, 1574, 1486, 1377 cm-1; 1HNMR 1.90 (s, 3H, CH3), 4.33 (s, 2H, 
CH2), 7.16-7.27 (m, 3H, 2'-H, 4'-H, 6'-H), 7.46 (d, 1H, 8-H), 7.52-7.55 (m, 1H, 5'-H), 7.68 (d, 1H, 7-H), 7.82 (s, 
1H, 5-H), 8.45 (s, 1H, NH), 9.09 (s, 1H, 4-H). Anal. C19H14NO5F (C, H, N). 
5.3.27.  3-Chlorophenyl 6-acetamidomethyl-2-oxo-2H-1-benzopyran-3-carboxylate (28c) 
3-Chlorophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27c) (0.25 g, 0.68 mmol) 
and TEA (0.103 g, 10 mmol) were suspended in acetic anhydride (10 mL, 0.106 mol). After 1 h, distilled water 
(50 mL) was added and the suspension was stirred at room temperature for 1 h. The resulting white precipitate 
was collected by filtration and washed with water: mp 241-242°C; IR 3067 (C-H arom), 1777 (C=O ester), 1760 
(C=O lactone), 1714 (C=O amide), 1647, 1621, 1572, 1472, 1376 cm-1; 1HNMR 1.90 (s, 3H, CH3), 4.33 (s, 2H, 
CH2), 7.29 (d, 1H, 6'-H), 7.42 (d, 1H, 8-H), 7.45-7.48 (m, 2H, 2'-H, 4'-H), 7.53 (t, 1H, 5'-H), 7.68 (d, 1H, 7-H), 
7.82 (s, 1H, 5-H), 8.46 (s, 1H, NH), 9.10 (s, 1H, 4-H). Anal. C19H14NO5Cl (C, H, N). 
5.3.28.  3-Bromophenyl 6-acetamidomethyl-2-oxo-2H-1-benzopyran-3-carboxylate (28d) 
3-Bromophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27d) (0.5 g, 1.2 mmol) and 
TEA (0.18 g, 1.8 mmol) were suspended in acetic anhydride (15 mL, 159 mmol) and heated under reflux for 1 h. 
After cooling, distilled water (50 mL) was added and the suspension was stirred at room temperature for 1 h. The 
resulting brown pasty precipitate was collected by filtration and washed with water. The crude product was 
suspended in ethyl acetate and the resulting precipitate was collected by filtration, washed with ethyl acetate and 
dried: mp 233.5-235°C; IR 3064 (C-H arom), 1776 (C=O ester), 1761 (C=O lactone), 1715 (C=O amide), 1646, 
1620, 1572, 1470, 1376 cm-1; 1H NMR 1.90 (s, 3H, CH3), 4.33 (s, 2H, CH2), 7.33 (d, 1H, 6'-H), 7.45-7.48 (m, 
2H, 5'-H, 8-H), 7.55 (d, 1H, 4'-H), 7.60 (s, 1H, 2'-H), 7.67 (d, 1H, 7-H), 7.82 (s, 1H, 5-H), 8.45 (s, 1H, NH), 9.10 
(s, 1H, 4-H). Anal. C19H14NO5Br (C, H, N). 
5.3.29.  3-Iodophenyl 6-acetamidomethyl-2-oxo-2H-1-benzopyran-3-carboxylate (28e) 
3-Iodophenyl 6-aminomethyl-2-oxo-2H-1-benzopyran-3-carboxylate chloride salt (27e) (0.25 g, 0.55 mmol) and 
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TEA (0.08 g, 0.8 mmol) were suspended in acetic anhydride (10 mL, 106 mmol). After 30 min, the mixture was 
gently heated for another 30 min. Then, distilled water (50 mL) was added and the suspension was stirred at 
room temperature for 1 h. The resulting white precipitate was collected by filtration and washed with water: mp 
223-224°C; IR 3056 (C-H arom), 1763 (C=O ester and lactone), 1718 (C=O amide), 1650, 1622, 1573, 1466, 
1376 cm-1; 1H NMR 1.90 (s, 3H, CH3), 4.32 (s, 2H, CH2), 7.28-7.35 (m, 2H, 5'-H, 6'-H), 7.46 (d, 1H, 8-H), 7.66-
7.73 (m, 3H, 2'-H, 4'-H, 7-H), 7.81 (s, 1H, 5-H), 8.46 (s, 1H, NH), 9.08 (s, 1H, 4-H). Anal. C19H14NO5I (C, H, 
N). 
5.4. Biological assays 
5.4.1. Chemoinvasion assay with HT 1080 fibrosarcoma cells 
5.4.1.1. Cell culture. Human fibrosarcoma HT 1080 cells were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS), penicillin—streptomycin (100 UI/mL-
100 µg/mL), 2 mM glutamine and 10 mM HEPES buffer at 37°C in a humid atmosphere (5% CO2 and 95% O2). 
5.4.1.2. Coating of culture wells with type IV collagen. Twenty four-well plates (Falcon, Becton-Dickinson, 
USA) and 6.5 mm polycarbonate filters (8 µm pore size) of Transwell cell culture chamber inserts (Costar, 
Netherlands) were coated with type IV collagen purified from human placenta diluted at 200 µg/mL in 
phosphate-buffered saline (PBS): 3 µL, then 5 µL, then 10 µL of this solution were added successively to the 
centre of filters. Collagen solution was then diluted to 100 µg/mL and two more additions were done. After each 
addition, coats were left to air-dry in a laminar flow hood under UV light. Thus, the final amount of collagen was 
about ±24 µg. Before use, coated plates and inserts were washed twice with sterile water and incubated for at 
least 1 h in serum-free DMEM at 37°C. 
5.4.1.3. Preparation of HT 1080 cell suspension. HT 1080 cells cultured in T-75 flasks (Nunc, Costar, 
Netherlands) at 70-80% confluence were collected, after trypsin-ethylene-diaminetetracetic acid treatment, in 20 
mL DMEM supplemented with  10% FCS and centrifuged at 1000 tr/min for 5 min. Cell suspension was placed 
for at least 30 min in a humid atmosphere at 37°C. Cells were then resuspended in 20 mL serum-free DMEM, 
centrifuged and finally diluted in the same medium supplemented with 1% bovine serum albumin   (BSA,   
fraction V, Sigma, USA) to a density of 6 x 105 cells/mL. Viability and count of cells were assessed in Thomas 
chamber after trypan blue staining. 
5.4.1.4. Invasion assay. The inhibitory potency of new synthetic coumarins (at 0.1, 1 and 10 µM) on HT 1080 
fibrosarcoma cell invasion and migration was assayed using a 'Boyden chamber' test. For chemoinvasion assays, 
type IV collagen membranes (see above) were used. Lower wells of chambers were filled  with  600 µL  DMEM  
supplemented with 20% FCS (acting as chemoattractant), 1% BSA and 6 µL of an inhibitor solution (10-5, 10-4 
and 10-3 M in DMEM supplemented with 10% dimethylsulphoxyde). Filters were recovered with 100 µL of cell 
suspension (6 x 10 cells), 200 µL DMEM supplemented with 0.1% BSA and 3 µL of inhibitor solution. 
Chambers were subsequently incubated for 48 h (in order to maintain a chemotactic gradient), media from both 
lower and upper wells were renewed after 24 h in a humid atmosphere at 37°C. After incubation, cells at the 
bottom of filters were fixed in 4% paraformaldehyde for 15 min at 4°C, permeabilised for 10 min in absolute 
methanol at -20°C and stained with Giemsa (4% in sterile water) (Fluka 48900) for 15 min. The exceeding dye 
was removed by washing with water and cells on the upper surface of filters were eliminated by scrapping with a 
cotton swab. Cells having reached the lower surface of the filters were visually counted using a light microscope 
(Vanox AH3, Olympus, Hamburg, Germany). Each essay was performed in triplicate (n = 3). Results were 
expressed as percentage (±s.d.) of the migration of control cells. 
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